Skip to main content
. 2015 Nov 25;27(4):699–705. doi: 10.1093/annonc/mdv545

Table 1.

Baseline patient and disease characteristics

mCRPC post-docetaxel
mCRPC chemotherapy-naïve
GS <8 (N = 503)
GS ≥8 (N = 545)
GS <8 (N = 479)
GS ≥8 (N = 517)
AA + P (n = 342) P (n = 161) AA + P (n = 356) P (n = 189) AA + P (n = 225) P (n = 254) AA + P (n = 263) P (n = 254)
Age, median (range), years 70 (42–95) 70 (39–87) 68 (45–86) 67 (43–90) 71 (45–95) 71 (50–90) 69 (44–90) 69 (44–90)
Extent of disease, n (%)
 Bone only 123 (36) 70 (43) 130 (37) 81 (43) 122 (54) 119 (47) 121 (46) 128 (50)
 Bone, soft tissue 219 (64) 91 (57) 226 (63) 108 (57) 103 (46) 135 (53) 142 (54) 126 (50)
ECOG PS, n (%)
 0 170 (76) 190 (75) 203 (77) 198 (78)
 1 55 (24) 64 (25) 60 (23) 56 (22)
 0–1 308 (90) 147 (91) 317 (89) 166 (88)
 2 34 (10) 14 (9) 39 (11) 23 (12)
Baseline PSA, median (range), ng/ml 123.3 (0.7–8099.9) 176.5 (0.6–3595.1) 141.7 (0.4–9253.0) 123.7 (3.8–10 114.0) 40.5 (0.0–3927.4) 36.7 (1.7–1782) 40.1 (0.6–1715.7) 36.3 (0.7–6606.4)
Baseline haemoglobin, median (range), g/dl 11.9 (8.1–16.1) 11.9 (8.4–15.7) 11.6 (7.3–15.2) 11.6 (7.2–16.5) 12.9 (9.3–16.6) 13.2 (9.3–15.7) 13.0 (7.2–16.2) 13.0 (7.0–15.6)
Baseline LDH, median (range), IU/l 216.0 (84.0–3373.0) 238.0 (143.0–2104.0) 226.0 (97.0–2232.0) 238.5 (123.0–1384.0) 185.0 (60.0–600.0) 184.0 (108.0–554.0) 187.0 (103.0–871.0) 181.0 (87.0–781.0)
Time from initial diagnosis to first dose, months 94.8 (5.8–237.2) 93.6 (21.1–267.8) 54.2 (6.9–226.6) 46.7 (2.0–215.7) 89.4 (5.9–267.2) 84.8 (8.8–331.5) 42.9 (5.6–235.6) 39.9 (3.0–217.9)

AA, abiraterone acetate; ECOG PS, Eastern Cooperative Oncology Group performance status; GS, Gleason score; LDH, lactate dehydrogenase; mCRPC, metastatic castration-resistant prostate cancer; P, prednisone; PSA, prostate-specific antigen.